MyFinsight
Home
Blog
About
Proceeds from sales and
maturities of marketable...
$39,445K
(-67.83%↓ Y/Y)
Proceeds from issuances
of common stock...
$17,924K
Proceeds from exercise of
stock options
$12K
(100.00%↑ Y/Y)
Net cash provided by
investing activities
$18,942K
(-74.20%↓ Y/Y)
Net cash provided by
financing activities
$17,936K
(3683.97%↑ Y/Y)
Canceled cashflow
$20,503K
Net increase in
cash, cash...
$14,091K
(58.18%↑ Y/Y)
Canceled cashflow
$22,787K
Purchases of marketable
securities
$20,502K
(-57.06%↓ Y/Y)
Purchases of property and
equipment
$1K
(-99.93%↓ Y/Y)
Stock-based compensation
expense
$2,477K
(-64.67%↓ Y/Y)
Depreciation and
amortization
$625K
(-73.20%↓ Y/Y)
Non-cash lease expense
$321K
(-66.74%↓ Y/Y)
Other receivables
-$310K
(-340.31%↓ Y/Y)
Contract assets
-$88K
(78.27%↑ Y/Y)
Prepaid expenses and
other current assets
-$52K
(93.59%↑ Y/Y)
Accounts receivable
-$24K
(87.63%↑ Y/Y)
Net cash used in
operating activities
-$22,787K
(64.93%↑ Y/Y)
Canceled cashflow
$3,897K
Licensing and other
third-party revenue
$1,499K
(-70.14%↓ Y/Y)
Other income, net
$1,057K
(122.14%↑ Y/Y)
Net loss
-$24,282K
(74.19%↑ Y/Y)
Canceled cashflow
$2,556K
Deferred revenue,
current and long-term
-$850K
(53.93%↑ Y/Y)
Accrued expenses and
other current...
-$744K
(69.17%↑ Y/Y)
Accounts payable
-$423K
(-154.65%↓ Y/Y)
Operating lease
liabilities
-$291K
(54.17%↑ Y/Y)
Other assets
$50K
(102.64%↑ Y/Y)
Accretion of discounts on
investments in marketable...
$44K
(-94.09%↓ Y/Y)
Total research and
development
$17,207K
(-70.38%↓ Y/Y)
General and
administrative
$6,530K
(-59.05%↓ Y/Y)
Other segment items
$3,101K
(-89.61%↓ Y/Y)
External costs
$9,566K
(-74.13%↓ Y/Y)
Internal costs
$7,641K
(-63.83%↓ Y/Y)
Back
Back
Cash Flow
Caribou Biosciences, Inc. (CRBU)
Caribou Biosciences, Inc. (CRBU)
source: myfinsight.com